On the other hand, although several trials and recent meta-analysis have suggested that n-3 PUFA may have beneficial effects on NAFLD patients, the outcomes on different biomarkers of fatty liver disease (AST, ALT, GGT or liver fat content by US) are sometimes heterogeneous [126,127,128,129,130]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.